Earnings summaries and quarterly performance for PACIFIC BIOSCIENCES OF CALIFORNIA.
Executive leadership at PACIFIC BIOSCIENCES OF CALIFORNIA.
Board of directors at PACIFIC BIOSCIENCES OF CALIFORNIA.
Research analysts who have asked questions during PACIFIC BIOSCIENCES OF CALIFORNIA earnings calls.
Jack Meehan
Nephron Research LLC
4 questions for PACB
Also covers: A, AVTR, BIO +17 more
KM
Kyle Mikson
Canaccord Genuity
3 questions for PACB
Also covers: AKYA, BDSX, CSTL +12 more
MC
Mason Carrico
Stephens Inc.
3 questions for PACB
Also covers: AKYA, CDNA, CSTL +13 more
Daniel Brennan
TD Cowen
2 questions for PACB
Also covers: A, ADPT, AVTR +24 more
David Westenberg
Piper Sandler
2 questions for PACB
Also covers: ADPT, AKYA, BLLN +13 more
SN
Subhalaxmi Nambi
Guggenheim Securities
2 questions for PACB
Also covers: AKYA, BRKR, CSTL +15 more
TS
Tejas Savant
Morgan Stanley
2 questions for PACB
Also covers: ADPT, AKYA, AVTR +19 more
Tycho Peterson
Jefferies
2 questions for PACB
Also covers: A, AVTR, BIO +22 more
AA
Alex Aylen
Canaccord Genuity
1 question for PACB
Douglas Schenkel
Wolfe Research, LLC
1 question for PACB
Also covers: A, AVTR, BRKR +21 more
Doug Schenkel
Wolfe Research LLC
1 question for PACB
Also covers: A, AVTR, BRKR +15 more
EB
Eve Burstein
Goldman Sachs
1 question for PACB
Also covers: EXAS, GH, ILMN +1 more
Harrison Parsons
Stephens
1 question for PACB
Also covers: CTKB, CUTR, HOLX
JA
Jake Allen
Goldman Sachs
1 question for PACB
Also covers: QTRX
Luke Sergott
Barclays
1 question for PACB
Also covers: A, AVTR, BRKR +19 more
Madeline Mollman
Wolfe Research, LLC
1 question for PACB
Also covers: MRVI, TWST, TXG
MP
Matthew Park
Cantor Fitzgerald
1 question for PACB
Also covers: AXGN, BVS, CERS +5 more
Salem Salem
Barclays
1 question for PACB
Also covers: GH, IQV, QGEN +3 more
Subbu Nambi
Guggenheim Securities
1 question for PACB
Also covers: ADPT, BOLD, BRKR +17 more
SJ
Sung Ji Nam
Scotiabank
1 question for PACB
Also covers: ADPT, BDSX, BNGO +9 more
TS
Tom Stevens
Cowen and Company
1 question for PACB
WR
William Ruby
TD Cowen
1 question for PACB
Also covers: BDSX, PSNL, SERA +1 more
YO
Yuko Oku
Morgan Stanley
1 question for PACB
Also covers: ADPT, GH, GRAL +7 more
Recent press releases and 8-K filings for PACB.
PacBio Completes Sale of Short-Read Sequencing Assets to Illumina
PACB
M&A
New Projects/Investments
Balance Sheet
- PacBio completed the sale of select intellectual property and other assets related to its short-read DNA sequencing technology to Illumina, Inc. on January 30, 2026.
- The company received $48.1 million in net cash proceeds from the transaction. The gross consideration was $50.0 million, with $1.9 million allocated to former Apton Biosystems equity holders for waiving milestone obligations.
- This sale is intended to sharpen PacBio's focus on its long-read sequencing platform and strengthen its balance sheet.
5 days ago
PacBio Completes Sale of Short-Read Sequencing Assets
PACB
M&A
New Projects/Investments
- PacBio completed the sale of select intellectual property and other assets related to its short-read DNA sequencing technology to Illumina, Inc.
- The transaction, which closed on January 30, 2026, resulted in PacBio receiving $48.1 million in net cash proceeds.
- This strategic decision aims to strengthen PacBio's balance sheet and sharpen its focus on the long-read sequencing market, including accelerating the development of SPRQ-Nx chemistry.
5 days ago
PacBio Reports Preliminary 2025 Financials and Unveils Spark Next Chemistry Impact
PACB
Guidance Update
Product Launch
Revenue Acceleration/Inflection
- PacBio anticipates preliminary 2025 revenue of $160 million, representing 4% growth, with Q4 2025 revenue reaching $44.6 million, a 14% year-over-year increase. The company ended 2025 with approximately $280 million in cash and investments and a reduced cash burn of around $110 million.
- Consumable shipments grew 19% in 2025, with the clinical market being the largest growth segment at 20% growth, and shipments to clinically focused customers increasing over 40%. Revio placements finished Q4 2025 with 21 units, and Vega achieved 42 placements in Q4, contributing to 140 placements for the year.
- The new Spark Next Chemistry, announced in October 2025, is expected to fundamentally reset the economics of long-read sequencing by enabling multi-use SMRT cells, increasing throughput by 25%, and allowing whole genome pricing at $300 a genome. This innovation is anticipated to drive significant market penetration and expand gross margins.
Jan 12, 2026, 6:30 PM
PacBio Reports Strong Q4 2025 Performance and Strategic Advances
PACB
Guidance Update
Revenue Acceleration/Inflection
Product Launch
- PacBio anticipates $160 million in revenue for 2025, reflecting 4% growth, with Q4 2025 revenue reaching $44.6 million, an increase of 14% year-over-year and 16% sequentially.
- The company reported a strong financial position with approximately $280 million in cash and investments and a significantly reduced 2025 cash burn of around $110 million.
- Growth was fueled by 19% growth in consumable shipments in 2025, a Q4 Revio pull-through of $242,000 per system per year, and 42 Vega placements in Q4, its best quarter. Shipments to clinically focused customers grew over 40% in 2025, helping to mitigate challenges in the academic funding market.
- The new SPRQ Next Chemistry, announced in October 2025, is a significant advancement expected to improve economics by enabling multi-use SMRT cells, increasing throughput by 25%, and allowing whole genome pricing at $300, which is anticipated to drive market penetration and expand gross margins.
Jan 12, 2026, 6:30 PM
PacBio Reports Preliminary Q4 2025 Revenue Growth and Details 2026 Strategy
PACB
Guidance Update
Product Launch
Revenue Acceleration/Inflection
- PacBio reported preliminary Q4 2025 revenue of $44.6 million, marking a 14% year-over-year increase and contributing to an anticipated $160 million in revenue for the full year 2025, representing 4% growth.
- The company significantly reduced its 2025 cash burn to approximately $110 million and maintained a strong financial position with around $280 million in cash and investments.
- The recently announced Spark Next Chemistry is poised to drive competitive economics for long-read sequencing, enabling whole genome pricing at $300 and is expected to increase market penetration in 2026.
- Clinical adoption was a major growth driver in 2025, with shipments to clinically focused customers growing over 40%, and this momentum is expected to continue in 2026, compensating for ongoing challenges in academic funding.
- The Vega sequencing platform, launched in late 2024, achieved 140 placements in 2025, including 42 in Q4, with 65% of these placements going to new customers.
Jan 12, 2026, 6:30 PM
PacBio Announces Preliminary Q4 and Full Year 2025 Revenue
PACB
Earnings
Revenue Acceleration/Inflection
- PacBio announced preliminary unaudited revenue of $44.6 million for Q4 2025, representing 14% year-over-year growth, and $160.0 million for full year 2025, an increase of 4% year-over-year.
- This revenue growth was primarily driven by strong Revio and Vega shipments and record consumables revenue.
- In 2025, PacBio also significantly reduced its cash burn and strengthened its financial profile.
- The company's ending cash, cash equivalents, and investments were approximately $279.5 million as of December 31, 2025.
Jan 12, 2026, 2:07 PM
PacBio Announces Preliminary Q4 and Full Year 2025 Revenue
PACB
Earnings
Guidance Update
Revenue Acceleration/Inflection
- PacBio announced preliminary unaudited revenue of ~$44.6 million for Q4 2025 and ~$160.0 million for full year 2025.
- This represents year-over-year revenue growth of 14% for Q4 2025 and 4% for full year 2025, driven by increased Revio and Vega sales and record consumables revenue.
- In 2025, PacBio significantly reduced its cash burn and strengthened its financial profile, with expectations for future growth catalyzed by increased real-world evidence in the clinic and lower costs from SPRQ-Nx.
- The reported financial information is preliminary and unaudited, subject to revision, and final audited results could differ materially.
Jan 12, 2026, 2:05 PM
PacBio and UC Davis Researchers Introduce CiFi Method
PACB
Product Launch
- PacBio announced CiFi, a new community-developed method that enables chromosome-scale, haplotype-resolved genome assemblies from a single sequencing run, even with limited sample material, by integrating chromatin conformation capture (3C) with PacBio HiFi long-read sequencing.
- CiFi offers significant advantages including improved mapping in repetitive regions, enhanced low input performance, and multi-contact resolution, which expands PacBio's multiomics capabilities and unlocks new customer use cases without requiring new hardware.
- A demonstration by UC Davis and PacBio on prairie and meadow vole showed that CiFi, combined with HiFi sequencing, can routinely deliver chromosome-scale, reference-quality assemblies using only one sequencing run.
Jan 8, 2026, 2:05 PM
Pacific Biosciences Discusses Spark Next Chemistry, Cost Parity, and 2027 Cash Flow Positive Goal
PACB
Product Launch
Guidance Update
Revenue Acceleration/Inflection
- Pacific Biosciences' new Spark Next chemistry aims to achieve near cost parity with short-read technology at approximately $300 per genome, significantly lowering the barrier to entry for long-read sequencing and attracting new customers.
- The company anticipates an inflection point for market share growth beyond its current 1-2%, driven by the value proposition of long-read technology and the cost-effectiveness offered by Spark Next.
- The Revio pipeline is strong, with 60% of recent Revio and Vega shipments going to customers new to PacBio, and the Spark Next launch is attracting new customers for Revio.
- Pacific Biosciences expects adjusted operating expenses for 2026 to be lower than 2025's projected $235 million to $240 million, and maintains its goal of achieving cash flow positive status by the end of 2027 through strategic initiatives and OpEx control.
- The Spark Next announcement has significantly strengthened the pipeline for large PopGen studies, with some now considering running 50% or more of their studies with PacBio, compared to 5-10% previously.
Nov 19, 2025, 4:00 PM
Pacific Biosciences Highlights Long-Read Sequencing Advantages and Growth Drivers
PACB
Product Launch
New Projects/Investments
Guidance Update
- PacBio's long-read sequencing technology demonstrates significant advantages over short-read, with studies showing it can identify 50% more structural variants and 93% of variants not visible with short read, providing a 99.9% whole genome and epigenomic information.
- The upcoming Spark Next chemistry is poised to achieve near cost parity with short-read sequencing, potentially reducing the cost to $300 per genome from $500-$600, which is expected to remove a major barrier and drive market share growth from the current 1-2%.
- Adoption of PacBio's technology is increasing, with 60% of new instrument buyers being new to long-read sequencing. Revio utilization reached 236 in the most recent quarter, and new chemistry is expected to boost this further by enabling more sample types and requiring four-fold less sample volume.
- The Spark Next announcement has significantly strengthened the pipeline for PopGen studies, with larger studies now considering running 50% or more of their projects with PacBio, compared to 5-10% previously, including the Long Life study of 7,800 whole genomes.
- The company aims to achieve cash flow positive by the end of 2027, supported by controlled operating expenses, with 2025 OpEx guided at $235 million to $240 million and 2026 adjusted OpEx expected to be lower than 2025.
Nov 19, 2025, 4:00 PM
Quarterly earnings call transcripts for PACIFIC BIOSCIENCES OF CALIFORNIA.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more